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PhosphorylationWe report the successful expression and puriﬁcation of functional human muscle glycogen synthase
(GYS1) in complex with human glycogenin-1 (GN1). Stoichiometric GYS1:GN1 complex was produced
by co-expression of GYS1 and GN1 using a bicistronic pFastBac™-Dual expression vector, followed by
afﬁnity puriﬁcation and subsequent size-exclusion chromatography. Mass spectrometry analysis
identiﬁed that GYS1 is phosphorylated at several well-characterised and uncharacterised Ser/Thr resi-
dues. Biochemical analysis, including activity ratio (in the absence relative to that in the presence of glu-
cose-6-phosphate) measurement, covalently attached phosphate estimation as well as phosphatase
treatment, revealed that recombinant GYS1 is substantially more heavily phosphorylated than would
be observed in intact human or rodent muscle tissues. A large quantity of highly-pure stoichiometric
GYS1:GN1 complex will be useful to study its structural and biochemical properties in the future, which
would reveal mechanistic insights into its functional role in glycogen biosynthesis.
 2015 The Authors. Published by Elsevier Inc. This is an openaccess article under the CCBY license (http://
creativecommons.org/licenses/by/4.0/).Introduction
Glycogen is a branched polymer of glucose that serves as a
repository of rapidly accessible energy and, thus plays an
important role in maintaining glucose and energy homeostasis at
both cellular and organism levels [1]. In mammals, liver and mus-
cle tissues are the major depots for glycogen storage, although to a
much lesser extent most tissues contain non-negligible levels of
glycogen. While the physiological importance of glycogen in mus-
cle and liver has been extensively documented in the context of
glucose homeostasis, recent evidence suggests a key role of glyco-
gen in brain (in both astrocytes and neurons) for cognitive function
[2] and also cancer cells for senescence and cellular growth [3].
Bulk biosynthesis of glycogen is mediated by glycogen synthase
which catalyses the addition of a-1,4-linked glucose units from
uridine diphosphate (UDP)3-glucose to a nascent glycogen chain,
and branching enzyme which forms a-1,6-glycosidic branchpoints[1]. In mammals, there are two glycogen synthase isoforms: muscle
glycogen synthase (GYS1; encoded by GYS1), which is ubiquitously
expressed, but most abundantly expressed in skeletal and cardiac
muscles, and the liver-speciﬁc isoform (GYS2; encoded by GYS2).
Activity of both isoforms is regulated by a complex interplay
between reversible phosphorylation at multiple sites and allosteric
regulators of which glucose-6-phosphate (G6P), an activator, plays
the most important role [1,4,5].
Besides glycogen synthase and branching enzyme, glycogenin is
another key enzyme involved in biosynthesis of glycogen. Glycog-
enin (GN) initiates glycogen synthesis by generating a short linear
(a-1,4-linked) chain of approximately 10 glucose units attached to
a conserved tyrosine residue (i.e., Y194 in human) [1,6]. Cohen and
colleagues ﬁrst reported that glycogen synthase puriﬁed from
rabbit skeletal muscle exists as a stoichiometric complex with
glycogenin [7] and proposed a key interplay between the two
enzymes in initiation of glycogen synthesis [6]. Subsequent studies
have demonstrated that glycogenin interacts with glycogen syn-
thase and enhances soluble overexpression of glycogen synthase
(when ectopically co-expressed with glycogen synthase in cultured
cell lines) [4,8]. This has led Khanna et al. [9] to make an attempt to
co-express GYS1 and glycogenin using MultiBac system in insect
cells, which resulted in a successful soluble expression and
puriﬁcation of large quantities of human GYS1 proteins. Direct
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ﬁrst reported by Skurat et al. [10] based on a yeast two-hybrid
study followed by cellular overexpression experiments and more
recently by an X-ray crystal structure of glycogen synthase in com-
plex with a C-terminal 34-residue fragment of GN [11].
Given the implication that the glycogen synthase:glycogenin
complex plays an important role in the initiation and elongation
of glycogen particles [6,11], it would be important to further
explore their molecular interaction and function as a complete
full-length complex for X-ray crystallographic and biochemical
property/functional studies. We here report a successful large-
scale expression and puriﬁcation of human GYS1 and human
GN1 in insect cells and also show biochemical properties of the
enzyme complex in cell-free assay systems.Materials and methods
Materials
Rabbit liver glycogen and pancreatic a-amylase were from
Sigma. Microcystin-LR was from Enzo Life Sciences. NADH was
from Apollo Scientiﬁc. Antibodies against pS8 GYS1 and pS8/S11
GYS1 were kindly donated by D. Grahame Hardie (University of
Dundee). pS641 GYS1 (#3891) and total GYS1 (#3893) antibodies
were from Cell Signaling Technologies. Total GYS1 (sc-81173)
and PP1c (sc-7182) antibodies were from Santa Cruz Biotechnol-
ogy. pS641/645 GYS1 (S486A, 3rd bleed) and GN1 (S197C, 1st
bleed) antibodies were generated by the Division of Signal Trans-
duction Therapy (DSTT) at the University of Dundee as previously
described [4]. Peroxidase conjugated secondary antibodies were
from Jackson Immunoresearch. Glutathione Sepharose 4B, NHS-
Sepharose FF, Superdex 200 3.2/300, Q-Sepharose HP and
Enhanced Chemiluminescent (ECL) reagent were from GE Health-
care. Gel ﬁltration standards were from Bio-Rad (151-1901). All
other reagents, unless otherwise indicated, were from Sigma.Expression and puriﬁcation of GYS1:GN1 complex
Genes coding for human GYS1 (NM 002103) and GST-tagged
GN1 (NM 004130) were cloned in a pFastBac™-Dual vector (Life
Technologies). A PreScission protease site was added between
GST and GN1. Recombinant bacmid was generated in DH10Bac™
cells (Life Technologies) and extracted using phenol:chloroform.
Unless speciﬁed otherwise, Spodoptera frugiperda (Sf9) cells (Life
Technologies) were cultured in suspension ﬂasks on a rotating
platform (110 RPM at 26 C) using an incubator shaker (Infors
HT) and Sf-900 II media following the supplier’s manual. Recombi-
nant progeny 1 (P1) baculovirus was produced in monolayer cul-
tures by transfecting 5 ml Sf9 cells (1.0  106 cells/ml grown in
25 cm2 ﬂasks) and was harvested after 6 days, aliquoted and stored
at 80 C. P2 virus was generated by infecting Sf9 suspension cul-
tures (1.5  106 cells/ml) with P1 virus (400 ll/100 ml cells). The
supernatant from this culture (P2) was harvested 72 h post-infec-
tion, and 3 ml were used to infect 600 ml of Sf9 suspension culture
(1.5  106 cells/ml), thus generating a P3 virus 72 h post-infection.
This culture (P3) was used at a 1:10 ratio to infect 2 L of Sf9 cells
(1.5–2.0  106 cells/ml) for protein production. Cells were grown
in suspension for 48 h and the cell pellets were washed in PBS prior
to harvesting in ice-cold lysis buffer (50 mM tris–HCl pH 7.8,
150 mM NaCl, 5% (v/v) glycerol, 1 mM EDTA, 1 mM EGTA, 1 mM
benzamidine, 0.2 mM PMSF, 5 lM leupeptin and 0.1% (v/v) 2-
mercaptoethanol). Cells were lysed using a continuous ﬂow cell
disruptor at 18,000 psi and the lysate was clariﬁed by centrifuga-
tion at 26,000g for 30 min. The supernatant was incubated on a
rolling platform for 1 h at 4 C with 1 ml of glutathione–Sepharoseresin, pre-equilibrated in low salt buffer (50 mM tris–HCl pH 7.8,
150 mM NaCl, 5% (v/v) glycerol, 1 mM EDTA, 1 mM EGTA, 1 mM
benzamidine and 0.1% (v/v) 2-mercaptoethanol). The beads were
washed with 10 column volumes (CV) of low salt buffer and 50
CV of high salt buffer (low salt buffer containing 500 mM NaCl),
followed by 10 CV of low salt buffer. Proteins were eluted by incu-
bating with 0.2 mg of GST-tagged PreScission protease for 16 h at
4 C. The eluate was concentrated to 0.7–1 ml and loaded on a
Superdex 200 10/300 column (GE Healthcare), pre-equilibrated in
25 mM tris–HCl pH 7.8, 150 mM NaCl and 1 mM TCEP. Eluted
peaks were analysed by SDS–PAGE, and fractions containing
>95% pure GYS1-GN1 complex were combined, concentrated to
2–3 mg/ml, snap frozen in liquid nitrogen and stored at 80 C.
Preparation of recombinant GST-PP1c
GST-tagged human PP1 catalytic subunit c was cloned into
pGEX6P-1 and expressed in BL21-CodonPlus (DE3)-RIL, cultured
in LB media supplemented with 1 mM MnCl2 at 18 C post induc-
tion with 0.2 mM IPTG. Cultures were harvested and lysed in
50 mM tris pH 7.5, 300 mMNaCl, 0.1 mM EDTA, 10% (w/v) glycerol,
1 mM MnCl2, 0.1% (v/v) 2-mercaptoethanol and 0.5 mM PMSF by
sonication. GST-PP1c was puriﬁed sequentially using glutathione
Sepharose 4B and Q-Sepharose HP and stored in 25 mM tris pH
7.5, 300 mM NaCl, 0.1 mM EDTA, 1 mM MnCl2, 0.1% (v/v) 2-
mercaptoethanol and 50% (v/v) glycerol at 20 C.
Mass spectrometry analysis
GYS1:GN1 complex was separated by SDS–PAGE and stained
with colloidal Coomassie staining solution. The GYS1 band was
excised, destained, in-gel reduced and alkylated with iodoaceta-
mide, then dried with acetonitrile followed by Speedvac. Samples
were digested with 60 ll of 2 lg/ml trypsin in 50 mM triethylam-
monium bicarbonate (TEAB) pH 8 overnight. Peptides were
extracted with an equal volume of acetonitrile, dried and
redissolved in 60 ll 5% acetonitrile/10 mM TEAB. Samples were
analysed by LC-MS on a 180  0.075 mm packed emitter coupled
to an Orbitrap velos mass spectrometry system. Peptides were sep-
arated over a 60 min gradient and the 10 most abundant precur-
sors detected in the Orbitrap at 60,000 resolution (2–4+ charge
state) were selected for MS/MS in the LTQ velos. To ensure the best
fragmentation spectrum for any phosphopeptide was obtained, the
precursors were fragmented using multistage activation (MSA) of
the precursor mass (m/z) minus 49, 32.33 and 24.25 Da (this repre-
sents the loss of H3PO4 from a 2+, 3+ or 4+ precursor ion). Raw ﬁles
were processed using Proteome Discoverer 1.4 and searched using
Mascot 2.3 against the Swissprot database (human only), allowing
for carbamidomethyl modiﬁcation of cysteine, oxidation of methi-
onine and phosphorylation of Ser/Thr/Tyr.
Phosphate content
Covalent phosphate was estimated by alkaline hydrolysis fol-
lowed by determination of released phosphate by complexometry
with a malachite green/molybdate reagent [12].
Electrophoresis and Western blotting
Samples were denatured in Laemmli sample buffer, separated
on 8–10% acrylamide tris–glycine gels and stained with Coomassie
brilliant blue (CBB) G-250 [13] or transferred to polyvinylidene
diﬂuoride membrane in Towbin buffer for 1 h at 100 V constant.
Membranes were blocked in 5% (w/v) milk prepared in tris-buf-
fered saline containing 0.1% (v/v) Tween-20 (TBST) for 1 h at room
temperature and incubated overnight in primary antibody.
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Fig. 1. Vector design and puriﬁcation of GYS1:GN1. (A) Diagram illustrating the key features of the bicistronic vector used to co-express human GYS1 and GST-tagged GN1.
Arrows indicate p10 and polyhedrin (polh) promoters. Ampicillin (AmpR) and gentamicin (GentR) resistance genes and origin of replication (pUC) are also labelled. (B)
Representative image of a CBB-stained SDS–PAGE gel of the puriﬁed recombinant GYS1:GN1 complex (2 lg). The relative mobilities of GYS1 and GN1 are indicated with
arrows. (C) Estimation of complex MW by size exclusion chromatography. GYS1:GN1 (5 lg) was fractionated on a Superdex 200 3.2/300 column equilibrated with 20 mM TES
pH 7.4, 150 mM KCl and 1 mM DTT. Shown inset is a calibration curve of Ka [(Vt  Vo)/(Ve  Vo), where Vt = total column volume, Vo = void volume and Ve = elution
volume)] vs. log10 MW prepared using protein standards.
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dase conjugated secondary antibodies for 1 h at room temperature
before detection with ECL reagent.In vitro dephosphorylation
GYS1:GN1 preparations were dephosphorylated with puriﬁed
GST-PP1c in reactions containing 20 mM TES pH 7.4, 100 mM
KCl, 5 mM MnCl2, 0.1 mM EGTA, 0.01% (w/v) BRIJ-35 and 0.1% (v/
v) 2-mercaptoethanol for 30 min at 30 C. Reactions were termi-
nated by the addition of 100 nM microcystin-LR prior to assay or
by denaturation in Laemmli sample buffer.In vitro deglycosylation
GYS1:GN1 preparations were incubated with 50 mU a-amylase
immobilised on NHS-Sepharose in 25 mM TES pH 7.4, 100 mM
NaCl and 5 mM CaCl2 for 30 min at 37 C. Reactions were termi-
nated by denaturation in Laemmli sample buffer.Glycogen synthase assay
Glycosyltransferase activity was determined using a coupled
spectrophotometric assay to monitor the formation of UDP in reac-
tions containing 50 mM TES pH 7.4, 100 mM KCl, 2 mM MgCl2,
1 mM phosphoenolpyruvate, 0.02% (w/v) bovine serum albumin,
2 mM 2-mercaptoethanol, 20 U/ml pyruvate kinase and 2 U/ml lac-
tate dehydrogenase. Enzyme preparations were incubated in 1%
(w/v) glycogen for 15 min at 30 C prior to assay and added to reac-
tions to yield a ﬁnal concentration of 0.1% (w/v) glycogen (5.5 mM
glucose equivalent.) and 1 mU GYS1. Reactions were started by the
addition of UDP-glucose and absorbance at 340 nm (A340) recorded
for 10 min at 30 C. Results are expressed as U/mg (GYS1 only, not
total protein), where 1 U = 1 lmol UDP formed per min at 30 C
assuming e340 [NADH] = 6.22 mM1 cm1. Kinetic parameters
were determined by non-linear regression using Graphpad Prism
v5.02 and the following equation:
v ¼ vmax  ½S
h
Khm þ ½Sh
where v = velocity, [S] = concentration of substrate or activator,
Km = concentration of substrate or activator that increases velocity
to 50% maximal stimulated activity and h = Hill coefﬁcient.Results and discussion
Co-expression of human muscle glycogen synthase (GYS)-1 and
human glycogenin (GN)-1 in a bicistronic bacmid in S. frugiperda
Taking advantage of a bicistronic expression vector (Fig. 1A), we
were able to successfully co-express human GYS1 with GST-tagged
GN1 in insect S. frugiperda (Sf9) cells. GYS1 and GST-GN1 co-eluted
after glutathione Sepharose afﬁnity puriﬁcation and subsequent
size-exclusion chromatography. The GYS1:GN1 complex produced
in this manner was >95% pure as assessed by SDS–PAGE and had a
yield of 1 mg/L of Sf9 culture (Fig. 1B).
Interestingly, the apparent molecular weight of the GYS1:GN1
complex estimated by size-exclusion chromatography was
529 kD, suggestive of a hetero-oligomeric structure with 4:4 stoi-
chiometry (Fig. 1C). This is similar to the size of the native
GYS1:GN1 active complex isolated from rabbit muscle tissues [7]
indicating the preparations are representative of a physiologically
relevant form. The 4:4 stoichiometry is also consistent with previ-
ous studies showing that Saccharomyces cerevisiae and Caenorhabdi-
tis elegansGYS form a functional tetramer [11,14] and that each GYS
monomer is capable of interacting with a GN1 C-terminus docking
motif [11]. A GYS1:GN1 complex withmolecular weight larger than
a 4:4 complex was also apparent from the small shoulder peak
(Fig. 1C). It is not clear if this represents a biologically relevant com-
plex or if this is a protein aggregate that appears under in vitro
conditions.GYS1:GN1 complex is stoichiometrically phosphorylated on key
regulatory sites
GYS is regulated by a complex interplay between positive allo-
steric stimulation by G6P binding and inhibition by covalent mod-
iﬁcation by reversible phosphorylation [1]. There are nine well-
characterised phosphorylation sites on GYS1 clustered at both
the N- and C-termini (Fig. 2A). Mutagenesis experiments have
revealed that sites 2, 2a, 3a and 3b play a dominant role in regula-
tion of GYS1 [15], whereas site 2 has the most inﬂuential role in
control of GYS2 activity [16]. Interestingly, phosphorylation of
these sites is also hierarchical whereby phosphorylation of site 2
by cAMP-dependent protein kinase (PKA) (or possibly by other
kinases such as glycogen phosphorylase kinase and AMP-activated
protein kinase [1,17,18]) enhances phosphorylation on site 2a by
casein kinase 1 (CK1) [18] and CK2-dependent phosphorylation
of site 5 primes the subsequent addition of four phosphates (4,
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Fig. 2. GYS1:GN1 prepared in S. frugiperda is heavily phosphorylated. (A) Domain organisation and known in vivo phosphorylation sites of human GYS1 (P13807).
Phosphorylation sites are labelled with the historical nomenclature (1–5) and sequence numbering from the initiator methionine. Protein kinases that phosphorylate these
sites (in vitro and in vivo) are indicated. The conserved arginine rich cluster required for G6P activation is also highlighted. (B) Dephosphorylation of GYS1:GN1 with PP1c
results in a marked increase in electrophoretic mobility. GYS1:GN1 was incubated with PP1c as described in methods and fractionated by SDS–PAGE prior to staining with
CBB. (C) Alternatively, GYS1:GN1 was incubated with a-amylase to remove carbohydrate. A representative CBB-stained gel is shown. (D) Post-translational modiﬁcations of
GYS1 were determined by LC-MS of tryptic peptides as described in methods. The full sequence of human GYS1 is shown (P13807). Sequence coverage is highlighted by
shading and mapped sites indicated with an asterisk. Key for (A): PhK – Phosphorylase kinase, CaMKII – Ca2+/calmodulin-dependent protein kinase, AMPK – AMP-activated
protein kinase, PKA – cAMP-dependent protein kinase, CK1/2 – casein kinase 1/2, PASK – Per-Arnt-Sim domain containing serine/threonine kinase, DYRK – dual speciﬁcity
tyrosine-regulated kinase, GSK3 – glycogen synthase kinase 3.
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trast, GN is a constitutively active enzyme so does not represent
a point of regulation. GYS1 expressed as a complex with GN1 in
insect cells was heavily phosphorylated as indicated by a signiﬁ-
cant increase in electrophoretic mobility after incubation with
the catalytic subunit of protein phosphatase 1 (PP1c) (Fig. 2B).
Indeed, estimation of covalently attached phosphate by alkaline
hydrolysis and Malachite green reagent suggested an average stoi-
chiometry of 6 mol:mol (phosphate:total protein), signiﬁcantly
higher than would be observed in intact muscle tissues. Removal
of carbohydrate by a-amylase digestion had little impact on the
mobility of GN apart from a subtle sharpening of the band suggest-
ing that the degree of glycosylation was modest consistent with
the highly phosphorylated, inactive state of GYS1, which would
be unable to extend the primed GN1 (Fig. 2C).The phosphorylation sites on GYS1 were mapped by tandem
mass spectrometry (MS/MS) of tryptic peptides. Sequence coverage
was 73% and peptides identiﬁed with a high degree of conﬁdence
are highlighted in the sequence of human GYS1 shown in Fig. 2D.
Identiﬁed sites and corresponding peptides are summarised in
Table 1. As expected, the highly acidic N-terminal peptide (GYS1
6–39, pI = 3.24, charge 8) containing sites 2 and 2a (S8/S11)
was not detected but the remaining conventional phosphorylation
sites at the C-terminus (3a, 3b, 4 and 5 or S641, S645, S653 and
S657) were present on a range of multiply phosphorylated species.
Indeed, many of these sites are apparently phosphorylated to near
stoichiometry given the very low abundance of non-phosphory-
lated species. Although we were unable to formally detect S649
(3c) in the MS/MS spectra, there was clear evidence of penta, hexa
and even hepta-phosphorylated forms of 641–650 so this site is
Table 1
Phosphorylation sites on GYS1 identiﬁed by LC-MS.
Site Classical
nomenclature
Sequence m/z [Da]
T54 53VtGDEWGDNYFLVGPYTEQGVR74 861.39
T372 372tNNFNVETLK381 630.29
S412 403KLYESLLVGsLPDMNK418 629.66
S486 475VIFHPEFLSSTsPLLPVDYEEFVR798 1451.23
S641 3a
636YPRPAsVPPsPSLSR650
636YPRPAsVPPSPSLSR650
636YPRPAsVPPsPSLSRHssPHQsEDEEDPR664
636YPRPAsVPPsPsLSRHssPHQsEDEEDPR664
651HSsPHQsEDEEDPR664
885.91
845.93
1214.47
1241.13
905.33
S645 3b
S647
S652
S653 4
S657 5
S710 1b
708RNsVDTATSSSLSTPSEPLSPTSSLGEER736 1024.82
708RNsVDTATSSSLSTPSEPLSPTSSLGEERN737 1062.83
S727
709NSVDTATSSSLSTPSEPLsPTSSLGEER736 1458.68
709NSVDTATSSSLSTPSEPLsPTSSLGEERN737 1010.8
R.W. Hunter et al. / Protein Expression and Puriﬁcation 108 (2015) 23–29 27likely also modiﬁed. Site 1b (S710) but not site 1a was also present,
though at relatively low abundance. In addition, a number of non-
conventional sites were identiﬁed (T54, T372, S412, S486, S652 and
S727), albeit at relatively low abundance. Several of these sites
have been identiﬁed by a recent study where human GYS1 was
overexpressed in insect cells [9] and also in global MS screens
[20–22]. It might be of interest to perform mutagenesis analysis
and examine the impact of these phosphorylation sites on the reg-
ulation of GYS1 activity and possibly cellular localisation, as the
physiological signiﬁcance of these non-conventional sites is
unknown.pS8 GYS1
pS8/11 GYS1
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activity determined using saturating UDP-glucose (4 mM) in the presence or absence o
Activity ratio (G6P/+10 mM G6P) for native (mock) and dephosphorylated (+PP1c) form
(C) Analysis of the major regulatory phosphorylation sites on recombinant GYS1 byWeste
buffer and immunoblotted with the indicated antibodies. ⁄Cell Signaling anti-GYS1 (#38GYS1:GN1 complex is functional and exhibits both allosteric and
phospho-dependent regulation
Glycosyltransferase activity of the GYS1:GN1 complex was
assessed using a coupled spectrophotometric assay with pyruvate
kinase/lactate dehydrogenase to follow the formation of UDP in
real time. As anticipated, due to the extensive phosphorylation of
GYS1 on key regulatory sites, the complex was essentially inactive
under standard assay conditions (4 mM UDP-glucose) in the
absence of G6P (Fig. 3A). Dephosphorylation with PP1c or the pres-
ence of saturating G6P resulted in a substantial increase in activity
to 17 U/mg GYS1. This value is somewhat lower than reported for
the classical preparation of GYS1 from rabbit skeletal muscle
(30 U/mg), but similar to recombinant preparations of GYS iso-
forms prepared in various mammalian cell lines [5,17] or Hi5 cells
[9]. The reason for this discrepancy is unclear, but may be due to as
yet unknown post-translational modiﬁcations not replicated in
heterologous expression systems. While it has been reported that
GYS1 can be modiﬁed by both O-GlcNAcylation [23] and lysine
acetylation [24], their functional signiﬁcance is uncertain. It is
not due to the common problem of partial proteolysis during iso-
lation of GYS1 from tissue, as the N- and C-termini are known to
be intact [25].
The ratio of activity in the absence and presence of G6P is com-
monly used as a readout of GYS phosphorylation status, albeit with
certain caveats [1] and ranges between 0.1 and 0.3 in skeletal mus-
cle depending on nutritional/hormonal status. The activity ratio
(G6P/+G6P) for native recombinant GYS1:GN1 was essentially
nil, but approached unity for PP1c-treated GYS1 (Fig. 3B) indicating
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Fig. 4. Kinetic parameters of GYS1:GN1. (A) Km(UDP-glucose) of the native, phosphorylated GYS1:GN1 complex (GYSb) was assayed as described in methods using saturating
G6P (10 mM). (B) Ka(G6P) of the native GYS1:GN1 complex (GYSb) was assayed using saturating UDP-glucose (4 mM). (C) GYS1 was quantitatively dephosphorylated with
PP1c and Km(UDP-glucose) determined in the absence of G6P. All results represent mean ± SD of three independent experiments.
Table 2
Kinetic properties of phospho-(GYSb) and dephospho-GYS1 (GYSa).
Parameter GYSb GYSa
Speciﬁc activity (U/mg)a 16.7 ± 0.3b 17.1 ± 0.9c
Km(UDPG) (mM) 0.096 ± 0.001d 0.118 ± 0.004
h(UDPG) 1.34 ± 0.03 1.37 ± 0.05
Ka(G6P) (mM) 0.311 ± 0.005c ND
h(G6P) 1.53 ± 0.02 ND
Phosphate contente 6.05 ± 0.23 Negligible
a Per mg GYS1.
b Determined using 4 mM UDP-glucose and 10 mM G6P.
c Determined using 4 mM UDP-glucose.
d Determined using 10 mM G6P.
e Mol phosphate per mol total protein (GYS1 + GN1).
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speciﬁc antibodies (Fig. 3C). This analysis also conﬁrmed the pres-
ence of phosphorylation at the N-terminal regulatory sites (S8/S11)
which were refractory to detection by LC–MS (Table 1). Detection
with the phospho-S8 antibody was relatively weak requiring sig-
niﬁcant ampliﬁcation compared to phospho-S8/S11, suggesting
that in most instances this region is phosphorylated in tandem.
This ﬁgure also demonstrates a notably underappreciated caveat
when immunoblotting GS in tissue/cell extracts, where the major-
ity of antibodies we have tested exhibit a marked phospho-depen-
dence (data not shown). Two examples are shown which illustrate
both extremes of this phenomenon, the widely used rabbit poly-
clonal antibody from Cell Signaling Technologies and the GS-7H5
mouse monoclonal antibody which have a striking preference for
dephospho and phospho-GYS1 respectively (equal loading is con-
ﬁrmed from the signal for GN1). Consequently, it is not unusual
to see reported data where the apparent expression of GYS is dif-
ferent between nutritional states or hormone treatment, but this
invariably correlates with changes in phosphorylation.Enzyme kinetic properties of GYS1:GN1
The kinetic properties of native, phosphorylated GYS1 (GYSb)
and the dephospho-form (GYSa) were determined using the cou-
pled spectrophotometric assay. Plots of ﬁtted data are shown in
Fig 4A–C and a summary of ﬁtted parameters is presented in Table 2.
As described previously, the native form of the complex (GYSb) was
effectively inactive, but could be stimulated by either dephospho-
rylation or the addition of G6P to essentially the same activity
(17 U/mg). Half maximal stimulation of GYSb with G6P [Ka(G6P)]
was 0.3 mM with a Hill coefﬁcient (h) > 1 indicating a degree of
positive cooperativity. The substrate activity relationship for UDP-
glucose ([Km(UDPG)] for GYSa and GYSb activated with G6P was
essentially identical at 0.1 mM. Reported values for kinetic prop-
erties of GYS1 (predominantly for the rabbit muscle preparation)
are highly variable as noted by Roach and Larner [26], depending
on the quality of the preparation and assay conditions thus it is dif-
ﬁcult to ﬁnd a deﬁnitive reference. Regardless, the two forms
assayed here exist at the extremes of phosphorylation state (either
stoichiometric or none) are not representative of physiological
states in vivo, but do compare favourably with values reported for
recombinant GYS1 puriﬁed from HEK293 cells which is also heavily
phosphorylated and essentially inactive in the absence of G6P [17].
These results demonstrate that the GYS1:GN1 complex as prepared
from insect cells is functional and exhibits properties similar to pro-
tein preparations from mammalian expression systems.
Conclusions
Although it has long been proposed that glycogen synthase and
glycogenin interact and this interaction plays a key role in glycogen
biosynthesis in muscle and liver, to our knowledge no one has
reported the preparation of a stoichiometric glycogen
R.W. Hunter et al. / Protein Expression and Puriﬁcation 108 (2015) 23–29 29synthase:glycogenin complex in large quantities. Taking advantage
of a bicistronic expression vector, we have set up conditions that
allow successful and reproducible production of functional human
GYS1:GN1 complex in insect cells. A large quantity of highly-pure
stoichiometric GYS1:GN1 complex will be an invaluable tool to
reveal its structural and biochemical properties for future studies.
Contribution statement
E.Z., K.S., F.S. and R.W.H. designed the study. E.Z. optimised the
protocol and produced and puriﬁed GYS1:GN1 complex. R.W.H.
carried out biochemical and functional experiments and N.M. per-
formed mass spectrometry analysis. F.S. supervised E.Z. R.W.H., KS,
E.Z. and N.M. wrote the manuscript.
Disclosure statement
The authors declare no conﬂict of interest associated with this
study.
Acknowledgments
We thank Mark Peggie (MRC Protein Phosphorylation and Ubiq-
uitylation Unit, Dundee) for vector cloning. E.Z. is supported by a
Human Frontiers Science Program (HFSP) fellowship and a Sir
Henry Wellcome postdoctoral fellowship. N.M. was funded by Can-
cer Research UK. F.S. was supported by Canadian Institutes of
Health Research grants MOP-126129 and MOP-57795 and Canada
research chairs in structural biology.
References
[1] P.J. Roach, A.A. Depaoli-Roach, T.D. Hurley, V.S. Tagliabracci, Glycogen and its
metabolism: some new developments and old themes, Biochem. J. 441 (2012)
763–787.
[2] M. Belanger, I. Allaman, P.J. Magistretti, Brain energy metabolism: focus on
astrocyte–neuron metabolic cooperation, Cell Metab. 14 (2011) 724–738.
[3] E. Favaro, K. Bensaad, M.G. Chong, D.A. Tennant, D.J. Ferguson, C. Snell, G.
Steers, H. Turley, J.L. Li, U.L. Gunther, F.M. Buffa, A. McIntyre, A.L. Harris,
Glucose utilization via glycogen phosphorylase sustains proliferation and
prevents premature senescence in cancer cells, Cell Metab. 16 (2012) 751–764.
[4] M. Bouskila, R.W. Hunter, A.F. Ibrahim, L. Delattre, M. Peggie, J.A. van Diepen,
P.J. Voshol, J. Jensen, K. Sakamoto, Allosteric regulation of glycogen synthase
controls glycogen synthesis in muscle, Cell Metab. 12 (2010) 456–466.
[5] A. von Wilamowitz-Moellendorff, R.W. Hunter, M. Garcia-Rocha, L. Kang, I.
Lopez-Soldado, L. Lantier, K. Patel, M.W. Peggie, C. Martinez-Pons, M. Voss, J.
Calbo, P.T. Cohen, D.H. Wasserman, J.J. Guinovart, K. Sakamoto, Glucose-6-
phosphate-mediated activation of liver glycogen synthase plays a key role in
hepatic glycogen synthesis, Diabetes 62 (2013) 4070–4082.
[6] C. Smythe, P. Cohen, The discovery of glycogenin and the priming mechanism
for glycogen biogenesis, Eur. J. Biochem./FEBS 200 (1991) 625–631.
[7] J. Pitcher, C. Smythe, D.G. Campbell, P. Cohen, Identiﬁcation of the 38-kDa
subunit of rabbit skeletal muscle glycogen synthase as glycogenin, Eur. J.
Biochem./ FEBS 169 (1987) 497–502.[8] A.V. Skurat, Y. Cao, P.J. Roach, Glucose control of rabbit skeletal muscle
glycogenin expressed in COS cells, J. Biol. Chem. 268 (1993) 14701–14707.
[9] M. Khanna, T. Imasaki, V.M. Chikwana, S. Perez-Miller, G.O. Hunter, A. Mosley,
Y. Takagi, T.D. Hurley, Expression and puriﬁcation of functional human
glycogen synthase-1 (hGYS1) in insect cells, Protein Expr. Purif. 90 (2013)
78–83.
[10] A.V. Skurat, A.D. Dietrich, P.J. Roach, Interaction between glycogenin and
glycogen synthase, Arch. Biochem. Biophys. 456 (2006) 93–97.
[11] E. Zeqiraj, X. Tang, R.W. Hunter, M. Garcia-Rocha, A. Judd, M. Deak, A. von
Wilamowitz-Moellendorff, I. Kurinov, J.J. Guinovart, M. Tyers, K. Sakamoto, F.
Sicheri, Structural basis for the recruitment of glycogen synthase by
glycogenin, Proc. Natl. Acad. Sci. U.S.A. 111 (2014) E2831–2840.
[12] P. Ekman, O. Jager, Quantiﬁcation of subnanomolar amounts of phosphate
bound to seryl and threonyl residues in phosphoproteins using alkaline
hydrolysis and malachite green, Anal. Biochem. 214 (1993) 138–141.
[13] D. Kang, Y.S. Gho, M. Suh, C. Kang, Highly sensitive and fast protein detection
with coomassie brilliant blue in sodium dodecyl sulfate–polyacrylamide gel
electrophoresis, Bull. Korean Chem. Soc. 23 (2002) 1511–1512.
[14] S. Baskaran, P.J. Roach, A.A. DePaoli-Roach, T.D. Hurley, Structural basis for
glucose-6-phosphate activation of glycogen synthase, Proc. Natl. Acad. Sci.
U.S.A. 107 (2010) 17563–17568.
[15] A.V. Skurat, Y. Wang, P.J. Roach, Rabbit skeletal muscle glycogen synthase
expressed in COS cells. Identiﬁcation of regulatory phosphorylation sites, J.
Biol. Chem. 269 (1994) 25534–25542.
[16] S. Ros, M. Garcia-Rocha, J. Dominguez, J.C. Ferrer, J.J. Guinovart, Control of liver
glycogen synthase activity and intracellular distribution by phosphorylation, J.
Biol. Chem. 284 (2009) 6370–6378.
[17] L. Bultot, B. Guigas, A. Von Wilamowitz-Moellendorff, L. Maisin, D.
Vertommen, N. Hussain, M. Beullens, J.J. Guinovart, M. Foretz, B. Viollet, K.
Sakamoto, L. Hue, M.H. Rider, AMP-activated protein kinase phosphorylates
and inactivates liver glycogen synthase, Biochem. J. 443 (2012) 193–203.
[18] H. Flotow, P.J. Roach, Synergistic phosphorylation of rabbit muscle glycogen
synthase by cyclic AMP-dependent protein kinase and casein kinase I.
Implications for hormonal regulation of glycogen synthase, J. Biol. Chem.
264 (1989) 9126–9128.
[19] C. Picton, J. Woodgett, B. Hemmings, P. Cohen, Multisite phosphorylation of
glycogen synthase from rabbit skeletal muscle. Phosphorylation of site 5 by
glycogen synthase kinase-5 (casein kinase-II) is a prerequisite for
phosphorylation of sites 3 by glycogen synthase kinase-3, FEBS Lett. 150
(1982) 191–196.
[20] H. Zhou, S. Di Palma, C. Preisinger, M. Peng, A.N. Polat, A.J. Heck, S. Mohammed,
Toward a comprehensive characterization of a human cancer cell
phosphoproteome, J. Proteome Res. 12 (2013) 260–271.
[21] K. Hojlund, B.P. Bowen, H. Hwang, C.R. Flynn, L. Madireddy, T. Geetha, P.
Langlais, C. Meyer, L.J. Mandarino, Z. Yi, In vivo phosphoproteome of human
skeletal muscle revealed by phosphopeptide enrichment and HPLC-ESI-MS/
MS, J. Proteome Res. 8 (2009) 4954–4965.
[22] A.N. Kettenbach, D.K. Schweppe, B.K. Faherty, D. Pechenick, A.A. Pletnev, S.A.
Gerber, Quantitative phosphoproteomics identiﬁes substrates and functional
modules of aurora and polo-like kinase activities in mitotic cells, Sci. Signal. 4
(2011) rs5.
[23] G.J. Parker, K.C. Lund, R.P. Taylor, D.A. McClain, Insulin resistance of glycogen
synthase mediated by o-linked N-acetylglucosamine, J. Biol. Chem. 278 (2003)
10022–10027.
[24] S. Zhao, W. Xu, W. Jiang, W. Yu, Y. Lin, T. Zhang, J. Yao, L. Zhou, Y. Zeng, H. Li, Y.
Li, J. Shi, W. An, S.M. Hancock, F. He, L. Qin, J. Chin, P. Yang, X. Chen, Q. Lei, Y.
Xiong, K.L. Guan, Regulation of cellular metabolism by protein lysine
acetylation, Science 327 (2010) 1000–1004.
[25] W.M. Zhang, M.F. Browner, R.J. Fletterick, A.A. DePaoli-Roach, P.J. Roach,
Primary structure of rabbit skeletal muscle glycogen synthase deduced from
cDNA clones, FASEB J. 3 (1989) 2532–2536.
[26] R.J. Roach, J. Larner, Covalent phosphorylation in the regulation glycogen
synthase activity, Mol. Cell. Biochem. 15 (1977) 179–200.
